Aravive begins Phase Ib part of ovarian cancer drug trial
Aravive has commenced the Phase Ib portion of a clinical trial evaluating the combination of AVB-S6-500 with standard-of-care to treat…
Aravive AVB-S6-500 ovarian cancer
